Victor Naik
Family · Lovington, NMNPI 1023736824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,485 and has fallen 63.5% since, to $542 in 2025. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$752
- AstraZeneca$465
- GSK$302
- Novo Nordisk$266
- Pfizer$249
- Lilly USA, LLC$163
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,31495%
- Education$1685%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $752 |
| AstraZeneca(2 entities) | 20 | $465 |
| GSK | 23 | $302 |
| Novo Nordisk | 16 | $266 |
| Pfizer | 11 | $249 |
| Lilly USA, LLC | 9 | $163 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $155 |
| Johnson & Johnson | 5 | $149 |
| Amgen | 9 | $145 |
| Boehringer Ingelheim | 7 | $137 |
| Bayer | 7 | $110 |
| UCB, Inc. | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Ironshore Pharmaceuticals Inc. | 4 | $59 |
| Astellas Pharma US Inc | 2 | $45 |
| Exact Sciences | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Merck | 2 | $33 |
| Nevro Corp. | 1 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Insmed, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Corium, LLC | 1 | $13 |
How this compares
$3,482 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,688 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $533 |
| Metoprolol Succinate | 23 | $514 |
| Atorvastatin Calcium | 57 | $402 |
| Omeprazole | 55 | $394 |
| Metformin Hcl | 34 | $377 |
| Losartan Potassium | 25 | $353 |
| Pantoprazole Sodium | 18 | $295 |
| Gabapentin | 33 | $250 |
| Levothyroxine Sodium | 41 | $244 |
| Bupropion XlBupropion Hcl | 15 | $229 |
| Ropinirole Hcl | 11 | $212 |
| Montelukast Sodium | 16 | $211 |
| Tamsulosin Hcl | 12 | $199 |
| Lisinopril | 28 | $193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $302 | $12,68820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Lovington
- Ocotlan MontoyaLovington$6K
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
- Barbara FranklinAlbuquerque$28K
- Laurie CrockettArtesia$19K
- Kaylene CribbsFarmington$17K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Jamie LujanLas Cruces$14K
- Katie BoylanRio Rancho$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.